Spinal cord injury (SCI) is a sudden disruption of the spinal cord's neural tissue within the spinal canal, caused by trauma, disease, or degeneration. This complex injury can vary greatly in its effects, with each case presenting distinct challenges. The severity and type of SCI depend on the level and nature of the damage, which can result in upper or lower motor neuron lesions, causing a range of motor, sensory, and autonomic dysfunctions.

In 2023, there were an estimated 959K total diagnosed prevalent cases of SCI across the 7MM, with the number expected to rise by 2034, as per DelveInsight analysis. According to estimates, there were approximately 19K acute (incidence) cases of SCI across the US in 2023, with the number expected to rise by 2034.

A spinal cord injury is a life-changing experience, and adapting to it can be difficult. However, with the help of a committed medical team and strong social support, individuals with spinal cord injuries can discover ways to participate in activities they love and live meaningful lives. Continued research efforts are focused on advancing our understanding of SCI's causes, developing new treatment approaches, and evaluating the effectiveness of interventions. These initiatives include preclinical research, clinical trials, and collaborative partnerships between academia, industry, and government, all aimed at improving treatment options for SCI patients.

The treatment options for SCI are still limited, with few approved therapies. At present, STEMIRAC is the only authorized treatment, available exclusively in Japan. LYRICA (pregabalin) is the only FDA-approved medication for neuropathic pain related to SCI, with generic versions also available.